Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.

@article{rnadttir1994LowdoseSI,
  title={Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.},
  author={Margr{\'e}t {\'A}rnad{\'o}ttir and Ljusk Ola Eriksson and John Germershausen and Hans Thysell},
  journal={Nephron},
  year={1994},
  volume={68 1},
  pages={57-62}
}
The high prevalence of hypercholesterolemia in kidney transplant recipients probably contributes to the high cardiovascular mortality in these patients. Except for diet, there is no generally recommended cholesterol-lowering treatment. We conducted a double-blind, randomized, placebo-controlled study with low-dose simvastatin in 40 ciclosporin (CS)-treated kidney transplant recipients during 16 weeks, focusing on side effects and dose finding. In the simvastatin group, the mean serum total and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

The effect of statins on cardiac allograft survival.

Transplantation proceedings • 2014
View 2 Excerpts

Similar Papers

Loading similar papers…